---

1. Recent Trends in the Diagnosis and Differential Diagnosis of Small Round Cell Tumors (SRCTs)

Overview

1. Ewing sarcoma / PNET family
2. Rhabdomyosarcoma (especially alveolar)
3. Neuroblastoma
4. Wilms tumor (nephroblastoma)
5. Lymphoblastic lymphoma/leukemia
6. Desmoplastic small round cell tumor (DSRCT)
7. Small cell carcinoma (neuroendocrine)
8. Merkel cell carcinoma
9. Synovial sarcoma (poorly differentiated)
10. Intraabdominal desmoplastic SRCT
11. SMARCB1-deficient tumors (rhabdoid tumors)
12. CIC-rearranged sarcoma, BCOR-altered sarcoma (newer entities)

---

Approach to Diagnosis

A. Morphology and Conventional Histopathology

• Ewing sarcoma: Sheets of uniform round cells with clear cytoplasm, lobular growth, Homer-Wright pseudorosettes (in PNET)
• Neuroblastoma: Homer-Wright rosettes, neuropil, schwannian stroma, ganglion cell differentiation
• Alveolar RMS: Alveolar pattern with rhabdomyoblasts (strap cells, tadpole cells), loss of cellular cohesion
• DSRCT: Nests/islands of round cells embedded in dense desmoplastic stroma, characteristic peritoneal location
• Lymphoblastic lymphoma: Starry-sky pattern, scant cytoplasm, convoluted nuclei

B. Immunohistochemistry (IHC) - Core Panel

C. Molecular Diagnostics - Current Gold Standard

• Quick Compendium of Clinical Pathology 5th Ed., Section 7.4.6

D. New and Emerging Entities (Post-WHO 2020)

1. CIC-rearranged sarcoma: Morphologically resembles Ewing sarcoma but shows CD99 positivity (variable), ETV4 nuclear expression; aggressive behavior, poorer prognosis than Ewing. CIC-DUX4 fusion by RNA sequencing.
2. BCOR-altered sarcoma (BCOR-CCNB3 sarcoma): Occurs predominantly in bone of males; BCOR-CCNB3 fusion t(X;p11). Shows BCOR expression by IHC.
3. EWSR1-non-ETS fusions: EWSR1-NFATC2, EWSR1-PATZ1 sarcomas - clinically and biologically distinct from classical Ewing sarcoma.
4. Round cell sarcomas with EWSR1 fusions: Distinct from classic Ewing even with same translocation when fused to non-ETS partners.

E. Next-Generation Sequencing (NGS) and RNA Sequencing

• RNA sequencing (RNA-seq) can detect known and novel fusions in a single assay
• Overcomes limitation of FISH (targets only known translocations)
• Identifies CIC-DUX4, BCOR-CCNB3, and other rare fusions not detectable by FISH panels
• DNA methylation profiling (Heidelberg classifier) - now used in specialized centers to classify CNS small round cell tumors (e.g., EWS-like vs. NB vs. AT/RT)
• Whole exome/genome sequencing for complex cases
• ddPCR for rare quantitative fusion detection

F. Cytogenetics and FISH

• FISH for EWSR1 break-apart remains standard of care for Ewing family
• MYCN amplification in neuroblastoma - detected by FISH; critical for risk stratification
• i(12p) or 12p gain in germ cell tumors helps differentiate from SRCT
• WT1-EWSR1 FISH for DSRCT

G. Differential Diagnosis Algorithm

• NUT carcinoma (NUT midline carcinoma): BRD4-NUT fusion, NUT IHC (>50% punctate nuclear)
• SMARCB1-deficient carcinoma
• IDH2-mutant sinonasal undifferentiated carcinoma
• SMARCA4-deficient carcinoma

• Rosette formation (Ewing, neuroblastoma)
• Lymphoglandular bodies (lymphoma)
• Cell cohesion (carcinoma > sarcoma)
• Ancillary IHC on cell block

H. Prognostic/Predictive Markers

• Ewing: EWSR1-ERG fusion confers worse prognosis than EWSR1-FLI1; STAG2 mutations associated with higher relapse risk
• Neuroblastoma: MYCN amplification, ALK mutation, segmental chromosomal aberrations (SCA) - high risk; whole chromosome gains - favorable
• Alveolar RMS: PAX3-FOXO1 fusion - worse prognosis than PAX7-FOXO1 or embryonal RMS
• Fusion-negative alveolar RMS: Now reclassified as embryonal RMS; better prognosis

---

2. Prognostic and Predictive Molecular Markers in Carcinoma Breast - With Special Emphasis on Recent HER2 Guidelines

A. Overview of Biomarker Categories

• Prognostic markers: Predict natural course of disease independent of treatment (e.g., tumor grade, Ki-67, TP53 mutation)
• Predictive markers: Predict response to a specific therapy (e.g., ER/PR for endocrine therapy, HER2 for anti-HER2 therapy, BRCA1/2 for PARP inhibitors)

---

B. Estrogen Receptor (ER) and Progesterone Receptor (PR)

• ER positive (Allred score ≥3, or ≥1% positive cells by ASCO/CAP): Predicts benefit from tamoxifen, aromatase inhibitors, CDK4/6 inhibitors
• PR: Additional prognostic value; PR-negative/ER-positive tumors have worse prognosis
• ER-low positive (1-10%): Controversial; 2020 ASCO/CAP update notes these should be reported as "ER low positive" and clinical decision-making may differ
• IHC for ER/PR uses Allred score or H-score systems

---

C. HER2 (ERBB2) - Major Recent Update

Standard HER2 Categories (2018/2023 ASCO/CAP):

• Group 1: HER2/CEP17 ratio ≥2.0; average HER2 ≥4.0 - Positive
• Group 2: Ratio ≥2.0; average HER2 <4.0 - Concurrent IHC 3+ → positive; IHC 2+ → positive; IHC 0/1+ → negative
• Group 3: Ratio <2.0; average HER2 ≥6.0 - IHC 3+ → positive; IHC 2+ → positive; IHC 0/1+ → negative
• Group 4: Ratio <2.0; average HER2 ≥4.0 and <6.0 - IHC 3+ → positive; IHC 2+ → positive; IHC 0/1+ → negative
• Group 5: Ratio <2.0; average HER2 <4.0 - Negative

The HER2-Low Revolution (2022-2024):

• The standard 2018 HER2 scoring remains unchanged (IHC 0/1+ = negative, 2+ = equivocal, 3+ = positive)
• A footnote is now mandated in HER2 IHC reports to flag HER2-low results (IHC 1+ or IHC 2+/ISH-negative) for potential T-DXd eligibility
• HER2-ultralow (faint incomplete membrane staining in ≤10% of cells, i.e., "0" but not truly zero) is NOT yet a formal ASCO/CAP category but is being investigated

HER2-Ultralow - Emerging Concept (2024):

• DESTINY-Breast06 (DB-06) trial (Bardia et al., NEJM 2024;391:2110-2122): T-DXd also showed benefit in HER2-ultralow (IHC 0 with incomplete faint staining) and HER2-low patients
• FDA approval (January 2025): T-DXd approved for HER2-low OR HER2-ultralow metastatic breast cancer (hormone receptor-positive)
• Companion diagnostic: Ventana Pathway HER2 (4B5) approved for HER2-low/ultralow assessment
• ASCO/CAP do not yet recommend "ultralow" as a formal category but provide a standardized reporting comment
• Prevalence: HER2-ultralow reported in ~10-29% of breast cancers

Key Challenge:

---

D. Ki-67 (Proliferation Index)

• >14% or >20% (cutoff varies): Predicts benefit from chemotherapy; component of Luminal A vs. B distinction
• Updated IKWG (International Ki-67 in Breast Cancer Working Group) recommendations: standardized counting methodology required; cutoffs of 5% (very low), 25% (high), with intermediate zone
• Ki-67 incorporated into modified Bloom-Richardson grade (Nottingham grade) indirectly

---

E. Multigene Assays - Genomic Profiling

---

F. Other Molecular Markers

• BRCA1/2 mutations: Germline - predictive for PARP inhibitors (olaparib, talazoparib) in HER2-negative metastatic disease; also predicts benefit from platinum chemotherapy; somatic BRCA in some triple-negative tumors
• PIK3CA mutations: Predicts benefit from alpelisib (PI3K inhibitor) in HR+/HER2- metastatic disease (SOLAR-1 trial)
• ESR1 mutations: Acquired resistance to aromatase inhibitors; elacestrant (SERD) active in ESR1-mutant tumors (EMERALD trial)
• AKT1 mutations: Capivasertib (AKT inhibitor) active in PIK3CA/AKT1/PTEN-altered HR+ disease (CAPItello-291 trial)
• TMB (tumor mutational burden) and MSI: Pembrolizumab approved for TMB-high (≥10 mut/Mb) tumors; MSI-high rare in breast cancer
• PD-L1: Pembrolizumab approved in PD-L1+ (CPS ≥10) triple-negative breast cancer (KEYNOTE-522 in neoadjuvant; KEYNOTE-355 metastatic)
• NTRK fusions: Larotrectinib/entrectinib - tumor-agnostic approval, rare in breast cancer
• TP53 mutations: Poor prognosis, especially in TNBC; emerging target
• Androgen receptor (AR): In TNBC LAR subtype - enzalutamide being evaluated

---

3. Molecular Classification of Endometrial Carcinoma

Background

---

TCGA Molecular Subtypes (Four Groups)

1. POLE Ultramutated (POLE mut) - ~10% of cases

• Defining feature: Somatic mutations in the exonuclease domain of POLE (DNA polymerase epsilon)
• Molecular profile: Extremely high mutation burden (>100 mutations/Mb), C→A and C→T transversions, MSI-H-like appearance but MMR intact
• IHC surrogates: p53 wild-type staining pattern, MMR proficient
• Prognosis: BEST - excellent even in high-grade tumors; paradoxically good outcome despite high-grade histology
• Treatment implications: May benefit from immune checkpoint inhibitors (pembrolizumab)
• Pathogenic mutations in exonuclease domain of POLE (e.g., P286R, V411L, A456P, S459F) must be distinguished from variants of uncertain significance

2. Mismatch Repair Deficient / Microsatellite Instability-High (MMRd/MSI-H) - ~25-30%

• Defining feature: Loss of mismatch repair proteins (MLH1, MSH2, MSH6, PMS2) or MSI-H
• Most common cause: Hypermethylation of MLH1 promoter (somatic, sporadic)
• Lynch syndrome (hereditary): Germline mutations in MMR genes - must be flagged; MLH1/PMS2 loss → reflexive MLH1 methylation testing; MSH2/MSH6 loss → Lynch likely
• Detection: MMR IHC (preferred in routine pathology) or MSI-PCR or NGS-based MSI analysis
• Prognosis: Intermediate - better than p53abn, worse than POLE
• Treatment implications: Pembrolizumab FDA-approved for MSI-H/MMRd endometrial carcinoma (KEYNOTE-158, RUBY trial)

3. Copy Number-High / p53 Abnormal (CNH/p53abn) - ~15-20%

• Defining feature: TP53 mutations (aberrant p53 IHC: diffuse strong or complete absence) + extensive copy number alterations (SCNA-high)
• Histology: Predominantly serous carcinoma and grade 3 endometrioid
• Molecular resemblance: Similar to high-grade serous ovarian carcinoma (TCGA serous-like)
• Detection: p53 IHC (aberrant = diffuse strong nuclear >80% cells OR complete absence in tumor with positive internal controls)
• Prognosis: WORST - aggressive behavior, high recurrence rates
• Treatment implications: Platinum-based chemotherapy; emerging role for PARP inhibitors, bevacizumab; BRCA1/2 mutations rare but possible

4. No Specific Molecular Profile (NSMP) / Copy Number-Low (CNL) - ~40%

• Defining feature: Exclusion diagnosis - POLE wildtype, MMR proficient, p53 wildtype
• Histology: Predominantly low-grade endometrioid carcinoma
• Prognosis: Intermediate-favorable, but heterogeneous group
• Emerging refinements: CTNNB1 (beta-catenin) mutations (exon 3) associated with worse outcomes within NSMP; L1CAM overexpression (>10%), ARID1A, PTEN, PIK3CA mutations common
• Prognostic tools within NSMP: CTNNB1 mutation, L1CAM, ER/PR status, LVSI

---

ProMisE Algorithm (Clinical Translation)

1. POLE sequencing (exonuclease domain mutations) → if mutant: POLE mut (regardless of other alterations)
2. MMR IHC (MLH1, MSH2, MSH6, PMS2) or MSI testing → if deficient: MMRd
3. p53 IHC → if aberrant: p53abn
4. All wild-type/normal → NSMP

---

Integration into FIGO 2023 Staging

• Stage IA POLE-mutated tumors: Favorable regardless of grade or LVSI (Stage IA3 with MMRd or POLE)
• Stage IIC: p53-abnormal with myometrial invasion ≥50% (high-risk)
• Molecular classification now changes staging and treatment decisions

---

WHO 5th Edition (2020/2023) Recommendations

1. POLE sequencing
2. MMR IHC / MSI testing (also for Lynch syndrome screening in all patients)
3. p53 IHC
4. Full staging with molecular reporting

---

Clinical Utility

---

4. Recent Advances in Classification of MDS

Terminology Change

---

Two Parallel Classification Systems Published in 2022

A. WHO 5th Edition (WHO-2022)

New Entities:

1. MDS with biallelic TP53 inactivation (MDS-biTP53): Defined by biallelic TP53 mutations (or TP53 mutation + loss of heterozygosity); blasts <20%; uniformly poor prognosis; resistance to conventional therapy; distinct from monoallelic TP53 mutation
2. Hypoplastic MDS (MDS-h): New formal entity characterized by hypocellular marrow (<30% cellularity in <70 years, <20% in ≥70 years) + dysplasia; must distinguish from aplastic anemia
3. MDS with fibrosis (MDS-f): Grade 2-3 fibrosis on reticulin stain + MDS morphology; distinct from MDS with increased blasts + fibrosis

Revised Categories:

• MDS with SF3B1 mutation (MDS-SF3B1): Previously MDS-RS (ring sideroblasts); now defined by SF3B1 VAF ≥5%; ring sideroblast percentage no longer required (unless SF3B1 wild-type, then MDS-RS retained as NOS)
• MDS with low blasts (MDS-LB): Replaces MDS-SLD/MLD; blast threshold <5% BM, <2% PB
• MDS with increased blasts (MDS-IB):
  • MDS-IB1: BM 5-9% or PB 2-4%
  • MDS-IB2: BM 10-19% or PB 5-19% or Auer rods
• Terminology unified: eliminates SLD/MLD distinction for blast-low MDS

Cytogenetics Update:

• del(5q), -7/del(7q), complex karyotype remain MDS-defining
• New: Cytopenic patients with MDS-defining cytogenetics but insufficient dysplasia → reclassified as CCUS (clonal cytopenia of undetermined significance) for most aberrations

B. International Consensus Classification (ICC 2022)

---

Molecular Drivers Integrated into Classification

• SF3B1: Most common spliceosome mutation in MDS (~30%); associated with ring sideroblasts, favorable prognosis; MDS-SF3B1 has indolent course
• TP53: Biallelic inactivation → MDS-biTP53 (WHO); universally poor prognosis; resistance to hypomethylating agents
• RUNX1: Co-mutation with SF3B1 seen in aggressive cases; familial RUNX1 syndrome
• ASXL1, EZH2, DNMT3A, TET2, IDH1/2, SRSF2: Incorporated in prognostic scoring
• del(5q): Isolated del(5q) remains a distinct favorable entity; responds to lenalidomide

---

IPSS-M (Molecular International Prognostic Scoring System)

• Incorporates 31 molecular variables + clinical parameters
• Dramatically improves on IPSS-R (cytogenetic/morphological) alone
• Provides individualized risk assessment
• Available as a web-based calculator
• Studies (PMID: 38154193) confirm IPSS-M outperforms IPSS-R for predicting AML transformation and overall survival

---

Pre-MDS States

• CHIP (Clonal Hematopoiesis of Indeterminate Potential): Somatic mutations without cytopenias or dysplasia
• CCUS (Clonal Cytopenia of Undetermined Significance): Cytopenia + clonal mutation, no dysplasia, no MDS-defining cytogenetics
• Aplastic anemia, PNH, VEXAS syndrome → can progress to MDS

---

Treatment Implications of New Classification

• MDS-SF3B1: Luspatercept (erythroid maturation agent, TGF-β trap) now approved; COMMANDS trial confirmed superiority over EPO
• MDS-biTP53: Clinical trials with APR-246 (eprenetapopt); allogeneic SCT if eligible
• MDS-IB2/MDS with high blasts: Venetoclax + azacitidine combinations under investigation; enasidenib (IDH2), ivosidenib (IDH1) for relevant mutations

---

5. Recent Advances in MRD (Measurable/Minimal Residual Disease)

Definition and Conceptual Shift

---

Methods of MRD Detection

1. Multiparameter Flow Cytometry (MFC)

• Sensitivity: 10⁻⁴ to 10⁻⁵ (detecting 1 leukemic cell in 10,000-100,000 normal cells)
• Two approaches:
  • LAIP (Leukemia-Associated Immunophenotype): Tracks the aberrant phenotype identified at diagnosis (AML)
  • DfN (Different from Normal): Identifies any population phenotypically distinct from normal hematopoiesis (AML and ALL)
• EuroFlow consortium: Standardized 8-color panels for MRD in ALL and AML
• Advantages: Fast (24-48 hrs), applicable to nearly all patients, detects any disease
• Limitations: Immunophenotypic shift post-treatment, interoperator variability, lower sensitivity than molecular methods

2. Quantitative PCR (qRT-PCR / RQ-PCR)

• Sensitivity: 10⁻⁴ to 10⁻⁵ (for fusion genes); 10⁻³ to 10⁻⁴ (for Ig/TCR rearrangements)
• Targets:
  • Fusion transcripts: BCR-ABL1 (CML, Ph+ ALL), RUNX1-RUNX1T1 (AML-M2), CBFβ-MYH11 (AML-M4eo), PML-RARA (APL), NPM1 mutations
  • Rearranged Ig/TCR genes (ALL, using ASO-PCR)
• NPM1 mutation PCR: Gold standard MRD marker in AML (~30% of AML); highly specific, detects 1:100,000
• PML-RARA (APL): Molecular remission (PCR negative after consolidation) is the treatment goal
• BCR-ABL1 in CML/Ph+ ALL: International Scale (IS) used; MR4.5 = <0.0032% IS

3. Next-Generation Sequencing (NGS) - Based MRD

• Error-corrected sequencing (ECS): Uses unique molecular identifiers (UMIs) to reduce sequencing error; sensitivity 10⁻⁵ to 10⁻⁶
• Targets: NPM1, FLT3-ITD, IDH1/2, DNMT3A, TET2, ASXL1, TP53 mutations in AML
• Limitation: Clonal hematopoiesis mutations (DNMT3A, TET2, ASXL1) persist in remission ("CHIP") and should not be used as MRD markers alone
• 2023 study (Li et al., Blood Cancer Journal, PMID: 37088803): NGS-defined MRD post-induction is a strong independent prognostic biomarker in AML
• NGS-based Ig/TCR clonotyping (ALL): LymphoTrack (Invivoscribe), ClonoSEQ (Adaptive Biotechnologies) - FDA cleared for B-ALL and MM

4. Digital Droplet PCR (ddPCR)

• Sensitivity: 10⁻⁵ to 10⁻⁶
• Quantifies rare events (droplets) independently; does not require standard curve
• Particularly useful for NPM1 mutations, FLT3-ITD, fusion genes at very low levels
• Being incorporated into clinical trials as primary MRD endpoint

5. ClonoSEQ (NGS-based Adaptive Immune Receptor Sequencing)

• FDA-cleared for MM and B-ALL MRD
• Clones identified at diagnosis are tracked using NGS-based sequencing of Ig heavy chain
• Sensitivity: 10⁻⁶
• "MRD negativity at 10⁻⁵" or "10⁻⁶" levels define deep responses

---

Clinical Significance

In ALL (Acute Lymphoblastic Leukemia):

• MRD after induction (day 29-33) is the most important prognostic factor
• MRD-negative patients have DFS ~70% vs. <40% for MRD-positive patients - Harrison's 22E
• MRD-based treatment stratification: MRD-positive after induction → intensification, consider allogeneic SCT
• Blinatumomab: BiTE antibody (CD3×CD19) now approved for MRD-positive B-ALL in CR (BLAST trial); reduces relapse risk in MRD+ patients

In AML:

• MRD negativity after induction and consolidation correlates with improved RFS and OS
• NPM1: Clearance of NPM1 mutation is standard MRD endpoint; persistent NPM1 MRD predicts relapse with long lead time
• FLT3-ITD: FLT3-ITD MRD can re-emerge; midostaurin and gilteritinib impact FLT3 MRD levels
• 2024 review (Zhao & Lan, Annals of Hematology, PMID: 39283479): Comprehensive review of MRD detection methods and prognostic implications in AML

In CML:

• Treatment-free remission (TFR): Patients achieving sustained deep molecular response (MR4.0 or better) can attempt TKI discontinuation; MRD monitoring essential
• European LeukemiaNet (ELN) milestones based on BCR-ABL1 IS levels at 3, 6, 12 months

In Multiple Myeloma (MM):

• MRD assessed by next-gen flow (NGF, EuroFlow) or NGS; sensitivity 10⁻⁵ to 10⁻⁶
• MRD negativity is a surrogate endpoint for OS in multiple clinical trials (IMWG consensus)
• Sustained MRD negativity in marrow and whole-body imaging (PET-CT) is emerging as deepest response criterion

In Solid Tumors - Emerging Frontier:

• ctDNA (circulating tumor DNA): MRD concept expanding to solid tumors
• Post-surgical ctDNA positivity (detected by tumor-informed or tumor-naive NGS) predicts high relapse risk in colorectal, lung, bladder, breast cancers
• DYNAMIC trial (colorectal cancer): ctDNA-guided chemotherapy decisions demonstrated non-inferiority with fewer patients receiving chemotherapy
• 2024 broad review (Chen et al., Leukemia, PMID: 38637690): MRD testing across hematological and solid cancers

---

MRD Standardization Efforts

• ELN (European LeukemiaNet): Published consensus recommendations for AML MRD (2018, updated 2021)
• EURO-MRD Consortium: Standardization of PCR methods for ALL
• EuroFlow: Standardization of flow cytometry MRD panels
• FDA guidance (2020): MRD as a biomarker and potential surrogate endpoint in hematologic malignancies
• HARMONY (EHA): Large consortium generating real-world MRD data in European populations

---

6. PD-1 - PD-L1 Axis and Its Role in Immunotherapy

The Immune Synapse and T Cell Activation

1. TCR recognition of antigen-MHC complex (Signal 1)
2. Co-stimulatory signal: CD28 on T cell + B7.1/B7.2 (CD80/CD86) on APC (Signal 2)

---

PD-1 (Programmed Cell Death Protein-1 / CD279)

• Gene: PDCD1 on chromosome 2q37
• Cell expression: Activated T cells (CD4+ and CD8+), B cells, NK cells, monocytes, dendritic cells
• Structure: Type I transmembrane protein; immunoglobulin superfamily; extracellular IgV domain; intracellular ITIM and ITSM motifs (ITIM = immunoreceptor tyrosine-based inhibitory motif)
• Ligands: PD-L1 (CD274/B7-H1) and PD-L2 (CD273/B7-DC)
• Normal function: Expressed on activated T cells to prevent excessive immune activation and protect tissues from immune-mediated damage (peripheral tolerance)
• In chronic antigen exposure (chronic infection, cancer): T cells become exhausted - progressive loss of effector function, associated with sustained PD-1 upregulation

---

PD-L1 (CD274/B7-H1) and PD-L2 (CD273)

• PD-L1: Widely expressed on tumor cells, tumor-infiltrating immune cells (macrophages, DCs), normal epithelial cells; induced by IFN-γ signaling (via JAK/STAT pathway and IRF-1); constitutively expressed in some tumors due to oncogenic signaling (e.g., EGFR, ALK, PI3K/AKT activation, MYC)
• PD-L2: More restricted expression; predominantly on macrophages and DCs; binds PD-1 with higher affinity than PD-L1

---

Signaling Mechanism

1. Phosphorylation of ITIM and ITSM motifs in the cytoplasmic tail of PD-1
2. Recruitment of SHP-2 (Src homology 2 domain-containing tyrosine phosphatase)
3. SHP-2 dephosphorylates CD28 and ZAP-70 → blocks downstream TCR signaling
4. Inhibition of PI3K/AKT, RAS/ERK pathways
5. Decreased production of IL-2, IFN-γ, TNF-α
6. Impaired cytotoxic T cell activity, reduced proliferation, induced anergy/exhaustion
7. Reduced expression of transcription factors: T-bet, eomesodermin

---

Tumor Immune Evasion via PD-L1

• Adaptive resistance: IFN-γ released by tumor-infiltrating T cells induces tumor-cell PD-L1 expression (JAK1/JAK2-STAT1-IRF1 pathway)
• Intrinsic expression: Constitutive PD-L1 via oncogenic drivers (e.g., EML4-ALK in NSCLC, HER2, EGFR signaling; TP53 loss; PTEN loss activating PI3K; MYC amplification)
• Epigenetic regulation: CMTM6 stabilizes PD-L1 protein by competing with STUB1 (ubiquitin ligase); CMTM6 knockdown reduces PD-L1 and restores T cell killing

---

Immune Checkpoint Inhibitors (ICIs) - Drugs Targeting PD-1/PD-L1

Anti-PD-1 Antibodies:

Anti-PD-L1 Antibodies:

Anti-CTLA-4 (synergistic with anti-PD-1):

• Ipilimumab + nivolumab: Melanoma, RCC, NSCLC, MSI-H CRC, MPM

---

Biomarkers for Response to PD-1/PD-L1 Therapy

1. PD-L1 Expression (IHC)

• Most widely used; measured as TPS (tumor proportion score) or CPS (combined positive score = tumor + immune cells)
• NSCLC: TPS ≥50% → pembrolizumab monotherapy first-line (KEYNOTE-024); TPS ≥1% → pembrolizumab + chemo
• TNBC: CPS ≥10 → pembrolizumab + chemo (KEYNOTE-522)
• Limitations: Inter-assay variability (4 different assays used clinically), spatial heterogeneity, dynamic expression

2. Tumor Mutational Burden (TMB)

• High TMB (≥10 mut/Mb by FoundationOne CDx): FDA-approved companion diagnostic for pembrolizumab across tumor types
• Higher neoantigen load → more targets for immune recognition

3. MSI-H / MMRd

• First tumor-agnostic FDA approval (2017): Pembrolizumab for MSI-H solid tumors
• Mechanism: High neoantigen load due to frameshift mutations from MMR failure

4. Tumor-Infiltrating Lymphocytes (TILs)

• High TIL density associated with response in melanoma, TNBC
• CD8+ T cells in tumor core vs. invasive margin: spatial distribution matters

5. Tumor Microenvironment (TME) Phenotypes

• Inflamed ("hot tumor"): TIL-rich, PD-L1+; best response to ICIs
• Immune excluded: TILs at periphery, not infiltrating; intermediate response
• Immune desert ("cold tumor"): No TILs; poor response
• CXCL9/CXCL10 gradients, VEGF (impairs T cell trafficking), transforming growth factor-β (TGF-β) activity in stroma influence TME phenotype

6. Emerging Biomarkers

• B cell signatures and tertiary lymphoid structures (TLS): Associated with better response in melanoma, sarcoma
• CXCR5+ PD-1+ T follicular helper cells: Linked to ICI response
• ctDNA dynamics: Early ctDNA reduction predicts response
• HLA class I expression: Loss → immune evasion; predicts resistance

---

Mechanisms of Resistance

---

Next-Generation Combinations and Emerging Checkpoints

• Anti-LAG-3 (relatlimab): Combined with nivolumab (Opdualag) approved in melanoma (RELATIVITY-047 trial) - first dual checkpoint blockade approval
• Anti-TIGIT: Tiragolumab being evaluated in NSCLC with atezolizumab
• Anti-TIM-3: Multiple trials ongoing
• Bispecific antibodies: PD-1×CTLA-4 (cadonilimab); PD-1×VEGF (ivonescimab - particularly active in NSCLC)
• PD-1 degraders and oral small molecule checkpoint inhibitors: In early development

---

Immune-Related Adverse Events (irAEs)

• Common: Fatigue, skin (rash, vitiligo), thyroid dysfunction, colitis, hepatitis
• Severe (Grade 3-4): Pneumonitis, myocarditis (rare but fatal), encephalitis, adrenal insufficiency
• Management: Steroids (prednisone 1-2 mg/kg for Grade 3), infliximab for steroid-refractory colitis; permanent discontinuation for severe irAEs

---

---

Principles of Automated Machines in Clinical Pathology

1. Introduction and Historical Context

• 1950s: Wallace Coulter develops the electrical impedance principle for blood cell counting - the first practical automated cell counter
• 1957: Leonard Skeggs introduces the first continuous-flow AutoAnalyzer (Technicon)
• 1960s-70s: Multi-channel continuous-flow analyzers; introduction of discrete analyzers
• 1981: Masahide Sasaki (Kochi Medical School, Japan) begins building the world's first fully automated laboratory using conveyor belts, electronic boards, and programmed robots
• 1989: Sasaki's automated laboratory revealed to Western audiences at AACC, sparking global adoption of total laboratory automation (TLA)
• 1990s onward: Commercial TLA systems emerge; today thousands of laboratories worldwide use TLA or partial automation systems

• Fixed automation: Instrument performs a single repetitive task
• Programmable automation: Instrument performs a variety of different tasks
• Intelligent automation: Instrument self-monitors and responds to changing conditions

---

2. Classification of Automation

A. Nonanalytical (Pre- and Post-Analytical) Automation

B. Analytical Automation

C. Total Laboratory Automation (TLA)

---

3. Preanalytical Automation

A. Specimen Identification and Labeling

B. Specimen Transport

1. Pneumatic tube systems (PTS): Pressurized air propels specimen carriers through network of tubes at 4-8 m/s; modern systems include soft-landing deceleration to minimize hemolysis/sample agitation. Connects wards, emergency department, and laboratory.
2. Automated guided vehicles (AGVs) / mobile robots: Navigate corridors autonomously using embedded floor sensors, optical guidance, or laser navigation; transport specimens on their own schedule without tube network infrastructure
3. Conveyor systems within laboratory: Segmented belt conveyors move specimens between modules within a TLA system; speed and routing controlled by process control software

C. Specimen Processing Automation

1. Automated centrifuges: Receive specimens on conveyor, centrifuge at preset conditions, return to line
2. Decappers/Uncappers: Remove caps from tubes without manual handling (reduces aerosol exposure)
3. Aliquoters: Pipette defined volumes from primary tubes into daughter tubes using robotic arms; prevents multiple centrifugations
4. Sorters: Sort tubes by test type, priority (STAT vs. routine), or destination analyzer
5. Recappers: Re-seal tubes after processing for storage or reflex testing
6. Specimen integrity checkers: Spectrophotometric assessment of hemolysis, lipemia, and icterus (HIL) indices performed automatically

• Automated analyzers measure absorbance at multiple wavelengths (e.g., 415 nm for hemolysis, 476 nm for icterus, 660/700 nm for lipemia)
• Rules-based algorithms correct results for mild interferents or flag/reject severe cases

---

4. Components of a Total Laboratory Automation (TLA) System

Laboratory Automation System (LAS) Software

• Reads specimen bar codes and queries LIS for ordered tests
• Calculates aliquot volume and number
• Routes specimens to appropriate analyzers
• Monitors analyzer availability and in-control status
• Performs autoverification: Rules-based decision making that automatically releases normal/acceptable results and flags exceptions for technologist review (per CLSI AUTO10-A guideline)
• Performs autoretrieve: Automatically retrieves specimens for repeat, reflex, or dilution testing
• Alerts on HIL, short samples, clot detection

• Open: Interfaces to analyzers from multiple vendors; flexible but complex
• Closed: Interfaces only to the vendor's own analyzers; tightly integrated but less flexible

---

5. Analytical Automation - Configurations

A. Unit Operations in an Analytical Process (Box 29.7, Tietz 7th Ed.)

1. Specimen identification
2. Specimen delivery
3. Specimen processing (deproteinization, dilution, etc.)
4. Sample introduction and internal transport
5. Sample loading and aspiration
6. Reagent handling and storage
7. Reagent delivery
8. Chemical reaction phase (incubation)
9. Measurement phase
10. Signal processing, data handling, and process control
11. Result delivery to the LIS

B. Analyzer Configurations

1. Continuous-Flow Analyzers (Historical)

• Technicon AutoAnalyzer (Skeggs, 1957): First automated chemistry analyzer
• Specimen and reagents flow as a continuous stream; separated by air bubbles (segmented flow)
• Single-channel (one analyte at a time) then multi-channel (parallel analysis of all channels)
• Limitation: Carryover between specimens, fixed test menu → replaced by discrete analyzers

2. Centrifugal Analyzers (Historical)

• Specimens and reagents loaded into discrete chambers in a spinning rotor
• Centrifugal force mixes contents and drives them to cuvettes on rotor periphery
• Single-specimen/multiple-chemistry or multiple-specimen/single-chemistry mode
• Mostly abandoned for high-volume clinical use; but centrifugal microfluidics now used in point-of-care devices (e.g., comprehensive metabolic panels on whole blood)

3. Discrete Analyzers - Current Standard

• Each specimen processed individually in separate reaction vessels (cuvettes)
• No carryover between specimens
• Flexible: Different tests for different specimens

4. Random-Access Analyzers - Most Common Modern Configuration

• Tests performed sequentially or prioritized (STAT) on a set of specimens
• Each specimen analyzed for a different selection of tests based on clinical orders
• Reagents stored onboard in vials, packs, or cartridges
• Test selection entered by: keyboard, LIS bar code instruction, or operator selection
• Profiles (panels) can be pre-defined
• Key advantage: Maximum flexibility; one analyzer can perform hundreds of different tests

---

6. Sample and Reagent Handling on Automated Analyzers

A. Specimen Aspiration

• Robotic probes (needles) aspirate a precise volume of specimen
• Cap-piercing technology: Probe penetrates rubber stopper without removing cap - reduces evaporation, aerosol, and contamination risk
• Liquid level sensing: Capacitance-based or pressure-based detection prevents short-sampling and probe clogging
• Clot detection: Pressure monitoring during aspiration detects clot obstruction

B. Reagent Handling

• Reagents stored onboard in refrigerated compartments (2-10°C) or ambient temperature
• Bar-coded reagent cartridges: Analyzer reads lot number, expiration date, and calibration data automatically
• RFID-tagged reagents: Some platforms use RFID for real-time inventory tracking
• Reagent volume monitoring triggers automatic alerts for low reagent levels
• Onboard stability: Modern reagent kits designed for weeks of onboard stability

C. Mixing

• Mechanical mixing by paddles, vortex, ultrasonic agitation, or aspiration-dispensing cycles
• Critical for adequate reaction kinetics

D. Incubation

• Temperature-controlled (typically 37°C) reaction zones
• Timed incubation before measurement

E. Reaction Vessels (Cuvettes)

• Disposable plastic cuvettes: Eliminates carryover; used once
• Permanent (glass/quartz) flow-through cuvettes: Automatically washed between samples; may have residual carryover
• Material must be optically clear at relevant wavelengths

---

7. Measurement Principles in Automated Analyzers

A. Spectrophotometry / Photometry

1. End-point (equilibrium) assays: Reaction goes to completion; absorbance measured at endpoint
2. Kinetic (rate) assays: Rate of absorbance change measured; useful for enzymes (e.g., ALT, AST, ALP, LDH); independent of incomplete reactions
3. Fixed-time kinetic: Absorbance measured at two fixed time points

B. Turbidimetry and Nephelometry

• Turbidimetry: Measures decrease in transmitted light as immune complexes form (antigen-antibody reaction); measured in same axis as light source (0°); used for quantifying proteins (CRP, immunoglobulins, complement), drug levels
• Nephelometry: Measures scattered light at an angle (typically 70-90° from incident beam); more sensitive than turbidimetry; used in dedicated protein analyzers (e.g., Siemens BN ProSpec, Beckman IMMAGE)

C. Fluorometry

• Measures emission of light at a longer wavelength after excitation at shorter wavelength
• Higher sensitivity than absorbance methods (detects 10⁻¹⁰ to 10⁻¹⁵ mol/L)
• Used in immunoassays (DELFIA - time-resolved fluorometry), therapeutic drug monitoring
• Time-resolved fluorescence (TRF): Uses lanthanide chelates (Europium, Terbium) with long fluorescence lifetimes; eliminates background autofluorescence → ultra-high sensitivity

D. Chemiluminescence

• Light emitted during a chemical reaction; no external light source needed → extremely low background
• Sensitivity: 10⁻¹⁵ to 10⁻¹⁸ mol/L (superior to fluorometry)
• Used extensively in automated immunoassay platforms for hormones, tumor markers, infectious serology, cardiac markers
• CLIA (chemiluminescent immunoassay): Acridinium ester or luminol as label
• ECLIA (electrochemiluminescence): Ruthenium complex + tripropylamine; triggered by electrical current at electrode surface; used in Roche Elecsys analyzers
• Platform examples: Abbott ARCHITECT (CMIA), Siemens ADVIA Centaur (CLIA), Roche Elecsys (ECLIA), Beckman Access (CLIA)

E. Potentiometry - Ion-Selective Electrodes (ISE)

• Measures electromotive force (EMF) generated across an ion-selective membrane
• Nernst equation: E = E° + (RT/nF) × ln[ion concentration]
• Used for: Na⁺, K⁺, Cl⁻, Ca²⁺, Li⁺, pH, pCO₂, pO₂
• Direct ISE (undiluted whole blood or plasma): Used in blood gas analyzers and POC devices; values differ from indirect ISE
• Indirect ISE (diluted specimen): Used in most automated chemistry analyzers
• Selective membrane materials: Glass (H⁺), valinomycin-doped PVC (K⁺), crystalline membrane (Cl⁻), ionophore-based membranes (Ca²⁺)

F. Amperometry / Coulometry

• Amperometry: Measures current generated at electrode surface by electrochemical reaction; used for glucose (glucose oxidase + oxygen reduction), pO₂ in blood gas analyzers
• Coulometry: Measures total charge; used in chloride titrators (Cotlove chloridometer)

G. Conductometry

• Measures electrical conductance of a solution
• Used in hematocrit measurement (some POC devices) and ion-selective electrode reference methods

---

8. Automated Hematology Analyzers

A. Coulter Principle (Electrical Impedance)

• Blood cells suspended in conductive electrolyte (saline) pass through a small aperture (~100 μm) between two electrodes
• Each cell, being non-conductive, displaces saline and produces a transient increase in electrical impedance
• Magnitude of impedance pulse ∝ cell volume → enables sizing
• Number of pulses = cell count
• RBCs, WBCs, and platelets identified by their sizes
• DC impedance: Measures cell size (volume)
• AC (radiofrequency) impedance: Penetrates cell membrane and measures nuclear and internal structural complexity (used in some platforms to distinguish cell types)
• "The Coulter principle can be thought of as an electrical analog of Archimedes' principle" - Tietz Textbook of Laboratory Medicine, 7th Ed.

B. Optical Light Scatter (Laser)

• Cells pass through a focused laser beam (usually helium-neon, 633 nm, or semiconductor diode)
• Forward scatter (FSC): At 2-3° from laser axis; correlates with cell size/volume
• Side scatter (SSC) / orthogonal scatter: At 90°; correlates with internal complexity (granularity, nuclear lobularity)
• Combination of FSC + SSC creates scatter plots (scattergrams) for cell differential
• Modern analyzers use multiple scatter angles: low-angle forward scatter (volume), high-angle forward scatter (nuclear complexity), side scatter (granularity)
• Differential counting: 5-part differential (neutrophils, lymphocytes, monocytes, eosinophils, basophils) based on multiparameter scatter analysis

C. Fluorescence-Based Differential

• Cells stained with DNA/RNA fluorescent dyes or labeled antibodies
• Reticulocytes: Stained with thiazole orange or oxazine 750 (RNA content); automated reticulocyte counts
• SYSMEX XN series: Uses multiple fluorescence channels (SF = side fluorescence, SFL = side-fluorescent light) + multiple scatter channels for differential, nucleated RBCs, immature platelet fraction (IPF), immature granulocyte fraction (IG%)

D. 5-Part Differential - Typical Approach (e.g., CELL-DYN, Sysmex, Advia):

E. Automated Slide Review

• Flagged samples (abnormal counts, morphology flags): Automatic slide-making and staining (e.g., Sysmex SP-10)
• Digital image analysis: Automated scanners (CellaVision DM96/DM1200; ADVIA 120) capture and classify cells using image recognition algorithms → AI-assisted morphology review
• Pathologist reviews flagged or classified cells on screen rather than at microscope

---

9. Automated Immunoassay Systems

Principles Used:

1. Competitive immunoassay (for small molecules: hormones, drugs): Labeled antigen competes with patient antigen for limited antibody binding sites; signal inversely proportional to analyte concentration
2. Sandwich (non-competitive) immunoassay (for large molecules: proteins, tumor markers): Patient antigen captured between two antibodies (capture + detection); signal directly proportional to analyte concentration
3. Labeled components:
   • Enzyme labels (ELISA): Horseradish peroxidase (HRP), alkaline phosphatase (ALP)
   • Chemiluminescent labels (CLIA/ECLIA): Acridinium esters, ruthenium complex → most sensitive, widely adopted in automated platforms
   • Fluorescent labels (FEIA, DELFIA): Time-resolved fluorescence
   • Radioisotope labels (RIA): Historical; replaced by non-isotopic methods
4. Separation methods:
   • Magnetic particle capture: Antibody-coated paramagnetic beads capture antigen; magnet separates bound from free fraction; washing steps remove unbound label
   • Solid-phase capture: Microparticle-coated tubes or wells

• Roche Elecsys (ECLIA on magnetic beads)
• Abbott ARCHITECT (CMIA - Chemiluminescent Microparticle Immunoassay)
• Siemens ADVIA Centaur (CLIA)
• DiaSorin LIAISON (CLIA)
• bioMérieux VIDAS (FEIA - enzyme-linked fluorescent assay)

---

10. Automated Coagulation Analyzers

---

11. Automated Urinalysis

1. Urine chemistry analyzer (automated reagent strip readers):
   • Reflectance photometry at multiple wavelengths on reagent pad strips
   • Measures pH, glucose, protein, blood, leukocyte esterase, nitrite, ketones, bilirubin, urobilinogen, specific gravity
   • Eliminates subjective visual color reading
2. Automated urine microscopy:
   • Digital flow morphology (IQ200): Cells, casts, crystals flow through channel; automated imaging and neural-network classification of formed elements
   • Cytocentrifugation + imaging: Concentrated sample, image analysis
   • Reflexes: Microscopy automatically triggered on abnormal dipstick results

---

12. Automated Blood Banking (Transfusion Medicine)

• Gel card technology (DiaMed ID-System, Ortho BioVue): Microcolumn with gel matrix; red blood cells after agglutination reaction trapped at top of gel (positive) or pellet at bottom (negative); automated reading by image analysis
• Solid-phase red cell adherence (SPRCA): RBC antigens adhere to microplate; automated plate readers
• Automated systems perform: ABO/Rh typing, antibody screen and identification, DAT, crossmatch, antigen typing
• IT systems track: donor history, blood component traceability, bar code chain of custody, transfusion-transmissible disease testing

---

13. Automated Microbiology

1. Automated blood culture systems (e.g., BACTEC, BacT/ALERT):
   • Continuous fluorescence or colorimetric CO₂ monitoring every 10 minutes
   • Automatic flagging of positive bottles
   • Principle: CO₂ generated by bacterial metabolism changes fluorescent sensor or colorimetric indicator at bottle bottom
2. Automated susceptibility testing / ID systems (e.g., VITEK 2, Phoenix):
   • Microcard/panel with 64-128 wells containing different substrates or antibiotics
   • Turbidity and colorimetric readings at multiple time points
   • Software calculates MICs and generates susceptibility reports
3. MALDI-TOF MS (Matrix-Assisted Laser Desorption/Ionization - Time-of-Flight Mass Spectrometry):
   • Bacterial/fungal colony applied to target plate + matrix compound
   • Laser ionizes sample; ions accelerated in electric field; separation by mass/charge ratio
   • Each organism produces a unique protein mass spectrum (fingerprint)
   • Database matching → identification in 2-5 minutes; replaces 24-48 hours of biochemical testing
   • Now the gold standard for rapid microbial identification
4. Automated urine culture (Kiestra, BD Kiestra TLA): Automated inoculation, streaking, incubation, imaging, and colony reading

---

14. Molecular Automation

1. Real-time PCR platforms (e.g., Roche LightCycler, Applied Biosystems QuantStudio):
   • Thermal cycling + fluorescence detection in one closed system
   • TaqMan probes, SYBR green, molecular beacons
   • Quantitative results; highly sensitive (10⁻⁶ copies)
2. Automated nucleic acid extraction: Magnetic particle-based or column-based extraction robots (e.g., Hamilton STARlet, Roche MagNA Pure)
3. High-throughput NGS platforms (Illumina, Ion Torrent): Massively parallel sequencing; highly automated library preparation and run setup
4. Digital droplet PCR (ddPCR): Partitioning reaction into thousands of droplets; absolute quantification without standard curve

---

15. Point-of-Care Testing (POCT) - Miniaturized Automation

---

16. Quality Control and Autoverification in Automated Systems

Quality Control

• Westgard rules: 1₂s, 1₃s, 2₂s, R₄s, 4₁s, 10x rules applied automatically by analyzer software
• Levey-Jennings charts: Automated display of QC trends
• Moving averages (bull algorithm): RBC indices (MCV, MCHC) monitored by running mean of patient samples - detects systematic drift without dedicated QC material

Autoverification (Auto-release)

• Range checks: Flag results outside reference intervals or critical values
• Delta checks: Compare current result to previous result for same patient; flag implausible changes
• Consistency checks: E.g., calculated osmolality vs. measured; anion gap
• Interference flags: HIL indices
• Clean results → auto-released to clinicians; problem results → held for technologist review

---

17. Laboratory Information System (LIS) Integration

• Bidirectional interfaces: LIS sends test orders to analyzers; analyzers send results back to LIS
• HL7 messaging protocol: Standard format for electronic exchange of laboratory data
• ASTM standard (E1394): Communication protocol for clinical instruments
• Middleware: Software layer between analyzer and LIS that performs data transformation, auto-verification, and reflex testing logic

---

18. Advantages and Limitations

---